144 related articles for article (PubMed ID: 1315755)
1. Mutations that alter the activity of the Rous sarcoma virus protease.
Grinde B; Cameron CE; Leis J; Weber IT; Wlodawer A; Burstein H; Bizub D; Skalka AM
J Biol Chem; 1992 May; 267(14):9481-90. PubMed ID: 1315755
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases.
Cameron CE; Ridky TW; Shulenin S; Leis J; Weber IT; Copeland T; Wlodawer A; Burstein H; Bizub-Bender D; Skalka AM
J Biol Chem; 1994 Apr; 269(15):11170-7. PubMed ID: 8157644
[TBL] [Abstract][Full Text] [Related]
3. Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates.
Grinde B; Cameron CE; Leis J; Weber IT; Wlodawer A; Burstein H; Skalka AM
J Biol Chem; 1992 May; 267(14):9491-8. PubMed ID: 1315756
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.
Cameron CE; Grinde B; Jentoft J; Leis J; Weber IT; Copeland TD; Wlodawer A
J Biol Chem; 1992 Nov; 267(33):23735-41. PubMed ID: 1331099
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the substrate-binding pockets of the Rous sarcoma virus and human immunodeficiency virus type 1 proteases.
Cameron CE; Grinde B; Jacques P; Jentoft J; Leis J; Wlodawer A; Weber IT
J Biol Chem; 1993 Jun; 268(16):11711-20. PubMed ID: 8389361
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.
Tözsér J; Zahuczky G; Bagossi P; Louis JM; Copeland TD; Oroszlan S; Harrison RW; Weber IT
Eur J Biochem; 2000 Oct; 267(20):6287-95. PubMed ID: 11012683
[TBL] [Abstract][Full Text] [Related]
7. Altered Rous sarcoma virus Gag polyprotein processing and its effects on particle formation.
Xiang Y; Ridky TW; Krishna NK; Leis J
J Virol; 1997 Mar; 71(3):2083-91. PubMed ID: 9032340
[TBL] [Abstract][Full Text] [Related]
8. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate.
Ridky TW; Kikonyogo A; Leis J; Gulnik S; Copeland T; Erickson J; Wlodawer A; Kurinov I; Harrison RW; Weber IT
Biochemistry; 1998 Sep; 37(39):13835-45. PubMed ID: 9753473
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for specificity of retroviral proteases.
Wu J; Adomat JM; Ridky TW; Louis JM; Leis J; Harrison RW; Weber IT
Biochemistry; 1998 Mar; 37(13):4518-26. PubMed ID: 9521772
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme subsites.
Ridky TW; Cameron CE; Cameron J; Leis J; Copeland T; Wlodawer A; Weber IT; Harrison RW
J Biol Chem; 1996 Mar; 271(9):4709-17. PubMed ID: 8617736
[TBL] [Abstract][Full Text] [Related]
11. Programming the Rous sarcoma virus protease to cleave new substrate sequences.
Ridky TW; Bizub-Bender D; Cameron CE; Weber IT; Wlodawer A; Copeland T; Skalka AM; Leis J
J Biol Chem; 1996 May; 271(18):10538-44. PubMed ID: 8631853
[TBL] [Abstract][Full Text] [Related]
12. Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: rethinking the "fireman's grip" hypothesis.
Strisovsky K; Tessmer U; Langner J; Konvalinka J; Kräusslich HG
Protein Sci; 2000 Sep; 9(9):1631-41. PubMed ID: 11045610
[TBL] [Abstract][Full Text] [Related]
13. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of the substrate binding pocket of murine leukemia virus protease and comparison with human immunodeficiency virus proteases.
Menéndez-Arias L; Weber IT; Oroszlan S
J Biol Chem; 1995 Dec; 270(49):29162-8. PubMed ID: 7493942
[TBL] [Abstract][Full Text] [Related]
16. Avian sarcoma leukemia virus protease linked to the adjacent Gag polyprotein is enzymatically active.
Arad G; Bar-Meir R; Almog N; Chorev M; Kotler M
Virology; 1995 Dec; 214(2):439-44. PubMed ID: 8553545
[TBL] [Abstract][Full Text] [Related]
17. Analysis of cleavage site mutations between the NC and PR Gag domains of Rous sarcoma virus.
Schatz G; Pichova I; Vogt VM
J Virol; 1997 Jan; 71(1):444-50. PubMed ID: 8985369
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases.
Weber IT
J Biol Chem; 1990 Jun; 265(18):10492-6. PubMed ID: 2162350
[TBL] [Abstract][Full Text] [Related]
19. Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins.
Bennett RP; Nelle TD; Wills JW
J Virol; 1993 Nov; 67(11):6487-98. PubMed ID: 8411352
[TBL] [Abstract][Full Text] [Related]
20. Identification of amino acid residues of the retroviral aspartic proteinases important for substrate specificity and catalytic efficiency.
Cameron CE; Burstein H; Bizub-Bender D; Ridky T; Weber IT; Wlodawer A; Skalka AM; Leis J
Adv Exp Med Biol; 1995; 362():399-406. PubMed ID: 8540349
[No Abstract] [Full Text] [Related]
[Next] [New Search]
